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ABSTRACT
Efficient gene silencing by RNA interference (RNAi)
in vivo requires the recognition and binding of the
5′- phosphate of the guide strand of an siRNA by the
Argonaute protein. However, for exogenous siRNAs
it is limited by the rapid removal of the 5′- phos-
phate of the guide strand by metabolic enzymes.
Here, we have determined the crystal structure of
human Argonaute-2 in complex with the metaboli-
cally stable 5′-(E)-vinylphosphonate (5′-E-VP) guide
RNA at 2.5-A˚ resolution. The structure demonstrates
how the 5′ binding site in the Mid domain of human
Argonaute-2 is able to adjust the key residues in the
5′-nucleotide binding pocket to compensate for the
change introduced by the modified nucleotide. This
observation also explains improved binding affinity
of the 5′-E-VP -modified siRNA to human Argonaute-2
in-vitro, as well as the enhanced silencing in the con-
text of the trivalent N-acetylgalactosamine (GalNAc)-
conjugated siRNA in mice relative to the un-modified
siRNA.
INTRODUCTION
The minimal complex required to achieve silencing through
small interfering RNA (siRNA) in human cells is composed
of human Argonaute-2 (hAgo2) and a short guide RNA
(20–23 bp) (1). Following formation of this RNA-induced
silencing complex (RISC), target mRNA recognition is an
extremely rapid process that results in target mRNA cleav-
age by hAgo2 and ultimately leads to mRNA degradation
(2). Though there are numerous points of contact between
the protein and the guide RNA backbone, the 5′-phosphate
binding site, which is located primarily in the Mid domain
with some contributions from the PIWI domain of hAgo2,
stands out as themost exquisite and critical. A combination
of ionic and hydrogen-bonding interactions ensures accu-
rate positioning of the 5′-phosphate of the guide strand and
results in precise cleavage at a single position on the mRNA
target (1,3–5). The utilization of siRNAs for therapeutic
purposes has revolutionized the field of drug discovery, and
a number of siRNA-based compounds have advanced into
clinical studies (6,7). This has brought the field closer to
the realization of RNAi-based therapies for a number of
previously ‘undruggable’ targets (6,7). Several compounds
that are currently undergoing clinical testing are based on
a strategy that results in safe and effective siRNA delivery
to the liver. The strategy utilizes a synthetic trivalent N-
acetylgalactosamine (GalNAc) ligand conjugated to the 3′
terminus of the sense strand of the siRNA. The GalNAc
moiety binds to the asialoglycoprotein receptor (ASGPR),
which is expressed on the cell surface of hepatocytes (8).
An issue that limits exogenous siRNA activity in vivo
is the rapid removal of the 5′-phosphate of the siRNA
by metabolic enzymes (9–11). The lack of a 5′-phosphate
results in inefficient incorporation of the guide strand
(also called the antisense strand), into hAgo2 (10). Chem-
ical modification of the 5′-phosphate, such as 5′-(E)-
vinylphosphonate (5′-E-VP), mimics phosphate properties
while maintaining metabolic stability that could lead to
more efficient guide incorporation into hAgo2 and there-
fore silencing (9,10,12–15). Although 5′-E-VP is a known
nucleoside modification utilized as a substrate for phos-
phate binding enzymes since 1976 (16), the evaluation of
this modification as a phosphate mimic in siRNAs has
been reported only recently (9,10,12–15). Additional inter-
nucleotide metabolic stability of siRNAs is attained by re-
placing the 2′-hydroxyl with the methoxy group (2′-OMe)
or fluoro group (2′-F) in addition to phosphorothioate (PS)
linkages between the nucleotides (8,17–22).
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Here, we solved the crystal structure of hAgo2 in com-
plex with a guide RNA carrying a 5′-E-VP modification
and studied the effect of the modification on binding to
the enzyme. hAgo2 can perfectly accommodate the modi-
fied RNA by slightly altering the 5′-phosphate binding site,
which also increases the affinity of the 5′-E-VP-modified
RNA to hAgo2 compared with that of an siRNA with
a canonical 5′-phosphate. In addition, 5′-E-VP-modified
siRNA had higher potency both in vitro and in vivo than
an siRNA of the same sequence with the same backbone
linkages and sugar modifications but with a 5′-phosphate.
MATERIALS AND METHODS
Oligonucleotide synthesis and analysis
Oligonucleotides were synthesized on an ABI Syn-
thesizer using commercially available RNA amidites,
5′-O-(4,4′-dimethoxytrityl)-2′-deoxy-2′-fluoro-, and 5′-O-
(4,4′-dimethoxytrityl)-2′-O-methyl- 3′-O-(2-cyanoethyl-
N,N-diisopropyl) phosphoramidite monomers of uridine,
4-N-acetylcytidine, 6-N-benzoyladenosine and 2-N-
isobutyrylguanosine using standard solid-phase oligonu-
cleotide synthesis and deprotection protocols. 5′-VPu
containing oligonucleotides were synthesized and depro-
tected following a modified protocol described in (9,10).
The GalNAc ligand was covalently linked to the 3′-end
of the sense (S) strand of the siRNA by a phosphodiester
linkage between the pyrrolidine scaffold as described
(8,10). Phosphorothioate linkages were introduced by
oxidation of phosphite utilizing 0.1 M 3-((N,N-dimethyl-
aminomethylidene)amino)-3H-1, 2, 4-dithiazole-5-thione
(DDTT) in pyridine. After deprotection, ion-exchange
HPLC purification followed by annealing of equimolar
amounts of complementary strands provided the desired
siRNA duplex by heating to 90◦C and slow cooling. The
siRNA samples were analyzed by mass spectrometry
and capillary gel electrophoresis and for endotoxin and
osmolality as described (8,10).
hAgo2-5′-(E)-vinylphosphonate TTR RNA complex struc-
ture determination
RNA-free hAgo2 was expressed and purified as previ-
ously described (23). The protein was then mixed with
5′-E-vinylphosphonate-2′-O-methyl-uridine-modified TTR
RNA at a 1:1.5 ratio. The complex was purified on a Su-
perdex 200 10/300 increase column (GE Lifesciences) and
crystallized as previously described (23). X-ray diffraction
data were collected at beamline 19-ID at theAdvanced Pho-
ton Source at Argonne National Laboratory. Diffraction
data were indexed, integrated, and scaled with autoPROC
(24). The structure was solved by molecular replacement
using the protein chain of the hAgo2 structure as a search
model (PDB 4F3T) with PHASER (25). The molecular re-
placement solution was subjected to rigid body refinement
in PHENIX (26) followed by simulated annealing refine-
ment prior to iterative manual model building in COOT
(27). Final translation/libration/screw motion (TLS) re-
finement of the model was performed with PHENIX with
manually selected TLS groups (Version 1.10.1-2155). The
final structure was refined to Rwork and Rfree values of 0.195
and 0.242, respectively. Figures were generated with Py-
MOL (the PyMOL Molecular Graphics System Version
1.6, Schro¨dinger).
hAgo2 filter binding assays
32P-labeled TTR RNA (100 pM) was incubated with 2-fold
serial dilutions (125 nM to 3.8 pM) of RNA-free hAgo2
for 30 min. Samples were applied to a slot blot apparatus
as described in (28). The protein–RNA complex was cap-
tured on a nitrocellulose membrane, and the free RNA was
captured on a subsequent nylon membrane. For the com-
petition assays, increasing concentrations of the competing
RNA and 100 pM of the labeled RNA were mixed with
1 nM (final concentration) of RNA-free hAgo2 and incu-
bated for 30 min. The protein-bound and unbound radiola-
beled RNA were visualized by phosphorimaging (Typhoon
7000, GEHealthcare) and quantified usingGeneTools soft-
ware (Synoptics). The results of three experiments were an-
alyzed using Prism software (GraphPad). Data are shown
as means of bound RNA/(bound RNA+unbound RNA)
plus and minus the standard deviation (SD). For the com-
petition assays results are shown as mean of [1 – (bound
RNA/(bound+unbound RNA))] ± SD.
In vitro gene silencing experiments
For transfection into primary mouse hepatocytes, 7.4 l of
Opti-MEM and 0.1 l of Lipofectamine RNAiMax (Invit-
rogen) were added to 2.5 l of siRNA per well of a 384-
well plate and incubated at room temperature for 15 min.
To each well was added 40 l of William’s E Medium (Life
Technologies) containing ∼5 × 103 primary mouse hepato-
cytes. Cells were incubated for 24 h prior to RNA isolation.
The RNA quantification was done using standard PCR
methods as previously described (8,29). Values are plotted
as a fraction of untreated control cells. Each sample was run
in technical duplicate, and each point represents the mean
of two biological samples ± % error. GAPDH served as the
internal control. IC50 values were determined and dose re-
sponse curves were generated using XLFit software.
In vivo gene silencing experiments
All procedures using mice were conducted by certified labo-
ratory personnel using protocols consistent with local, state,
and federal regulations. Experimental protocols were ap-
proved by the Institutional Animal Care and Use Commit-
tee, the Association for Assessment and Accreditation of
Laboratory Animal Care International (accreditation num-
ber: 001345), and the Office of Laboratory Animal Welfare
(accreditation number: #A4517-01). C57BL/6 female mice,
aged 6–8 weeks, acquired from Charles River Laboratories
were dosed subcutaneously with a volume of 10 l/g of
body weight (n = 3 per group). The control group received
phosphate buffered saline (PBS). Liver samples were col-
lected from animals dosed with 5′-HO-TTR and 5′-E-VPu-
TTR siRNA 7 days post-dose. TTR mRNA levels were
quantified using the methods described earlier (8).
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Quantification of whole liver andAgo2-associated siRNA lev-
els
Mice were sacrificed on day 7 post-dose, and livers were
snap frozen in liquid nitrogen and ground into powder for
further analysis. Total siRNA liver levels were measured by
reconstituting liver powder at 10 mg/ml in PBS contain-
ing 0.25% Triton-X 100. The tissue suspension was further
ground with 5-mm steel grinding balls at 50 cycles/s for 5
min in a tissue homogenizer (Qiagen TissueLyser LT) at
4◦C. Homogenized samples were then heated at 95◦C for
5 min, briefly vortexed and allowed to rest on ice for 5 min.
Samples were then centrifuged at 21 000 x g for 5 min at
4◦C. The siRNA-containing supernatants were transferred
to new tubes. siRNA sense and guide strand levels were
quantified by stem loop reverse transcription followed by
Taqman PCR (SL-RT QPCR) based on a previously pub-
lished method (9,30).
Ago2-bound siRNA from mouse liver was quantified by
preparing liver powder lysates at 100 mg/ml in lysis buffer
(50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 2mM EDTA,
0.5% Triton-X 100) supplemented with freshly added pro-
tease inhibitors (Sigma-Aldrich, P8340) at 1:100 dilution
and 1 mM PMSF (Life Technologies). Total liver lysate
(10 mg) was used for each Ago2 immunoprecipitation (IP)
and control IP. Anti-Ago2 antibody was purchased from
WakoChemicals (CloneNo.: 2D4). Controlmouse IgGwas
from Santa Cruz Biotechnology (sc-2025). Protein G Dyn-
abeads (Life Technologies) were used to precipitate anti-
bodies. Ago2-associated siRNAs were eluted by heating (50
l PBS, 0.25% Triton; 95◦C, 5 min) and quantified by SL-
RT QPCR as described (10,30).
RESULTS
The 5′ binding pocket of hAgo2 can accommodate modified
RNA nucleotides
Wepreviously described a simple and robustmethod to pro-
duce significant amounts of RNA-free hAgo2 (23). This
method allows us to load hAgo2 with a particular guide
RNA and to measure the binding affinity of any oligonu-
cleotide to hAgo2.Here, we used thismethod to load hAgo2
with an oligonucleotide modified on the 5′ terminus with
5′-(E)-vinylphosphonate 2′-O-methyl (2′-OMe)-uridine (5′-
E-VPu) (Figure 1A). The sequence used in this study was
the mouse analogue of an siRNA guide strand designed to
target the mRNA encoding transthyretin (TTR), a protein
that misfolds and accumulates as amyloid fibrils in patients
with certain forms of amyloidosis (31). The sequence of the
RNA oligonucleotide modified with 5′-E-VPu (5′-E-VPu-
TTR RNA) is shown in Figure 1C. The complex was crys-
tallized and the structure determined to 2.5-A˚ resolution
(Supplementary Table S1).
The overall structure of the complex is very similar to that
of the complex of hAgo2 with unmodified miR-20a (23).
5′-E-VPu-TTR RNA is threaded along the Mid, PIWI, N,
and PAZ domains with the modified 5′-end anchored in
the Mid domain and the 3′-end in the PAZ domain (Fig-
ure 1B). Despite sequence differences, the 5′-E-VPu-TTR
modified guide RNA superimposes almost perfectly with
the miR-20a guide RNA of the previously solved miR-20a-
hAgo2 complex. The RMSD is 0.347 A˚ for nucleotides 2–
10 and is 1.215 A˚ overall (Figure 1C and Supplementary
Figure S1A). Previous structural studies of Argonaute com-
plexes established that all interactions between eukaryotic
Argonautes and the guide RNA beyond that with the first
nucleotide are mediated by the phosphate/sugar backbone
in a sequence-independent manner (23,28,32–35).
Almost all of the differences between the 5′-E-VPu-TTR
RNA and the miR-20a RNA are restricted to the 5′ nu-
cleotide (Figure 1D and Supplementary Figure S1B). The
position of the phosphorous atom of the 5′ moieties of
the two guide RNAs are perfectly aligned between the two
structures underlining the precise organization of that bind-
ing site. The non-bridging oxygens of the 5′-E-VPu moi-
ety are slightly rotated compared to the 5′-phosphate of
miR-20a, but the distances between side chains that com-
pose the 5′-phosphate binding site, namely, K533, K570,
K566, and R812 side chains and the C-terminal carboxy-
late of A859 are similar in both structures. The double bond
of the 5′-E-VPu moiety, which replaces the bridging oxy-
gen of a canonical phosphate, produces a 1-A˚ shift in the
position of the sugar group and the uracil base relative to
the positions in miR-20a. Strikingly, all the hAgo2 residues
that interact with both the sugar ring and the uracil base
are shifted accordingly to accommodate the change in their
positions. Y529, an essential residue in the 5′-phosphate
binding pocket, is similarly tilted in the complex with 5′-E-
VPu-TTR RNA, preserving the stacking interaction with
the uracil base and maintaining the interaction between its
hydroxyl group and one of the oxygens of the 5′-phosphate.
In addition, this 1-A˚ movement brings the uracil base close
to the specificity loop, G524-T526, which reads the iden-
tity of the first nucleotide base, by 0.7 A˚. This results in a
much tighter interaction of the Watson-Crick edge and the
backbone carbonyl oxygen of G524 than is observed with
miR-20a and interactions with the amide groups of G524
and K525 that are not observed in the complex with the un-
modified RNA (Figure 1D).
Finally, Q548, which interacts with the 2′-OH of the un-
modified nucleotide in the 5′ position of miR-20a, interacts
with the oxygen of the 2′-OMe of the 5′-E-VPu modifica-
tion demonstrating that the change from a hydroxyl to a
methoxy group did not interfere with binding. Therefore,
neither the (E)-vinylphosphonate nor the 2′-sugar modifi-
cation of the 5′-end of the guide strand disrupts binding to
hAgo2 and features of this modification may enhance bind-
ing in the 5′ binding pocket of hAgo2. Thus, replacing the
5′-P of a guide RNA with the modified 5′-E-VPu and the
hydroxyl group to a methoxy are not only possible, but ap-
pear to be favorable for hAgo2 binding over a ‘natural’ 5′-
nucleotide with a phosphate.
The 5′-(E)-vinylphosphonate modification at the 5′-end of the
guide strand increases affinity for hAgo2
To test the effect of the 5′-E-VPu modification, we mea-
sured binding affinities of various TTR guide RNAs of the
same sequence and RNA-free hAgo2 using a filter-binding
assay (Table 1). A 32P-labeled TTR guide RNA with no
chemical modifications had a binding affinity of 1.1 nM
for hAgo2 (Figure 2A), which is ∼50 times tighter than
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Figure 1. The crystal structure of hAgo2 in complex with 5′-E-VPu-TTR guide RNA. (A) The chemical structure of 5′-(E)-vinylphosphonate 2′-O-methyl
(2′-OMe)-uridine used in the modified guide RNA. (B) Overall structure of hAgo2 in complex with 5′-E-VPu-TTR RNA with the N-domain in blue, the
L1 domain in light blue, the PAZ domain in red, the L2 domain in yellow, theMid domain in green, and the PIWI domain in purple. The RNA is colored in
gold; the dashed gold line represents bases 11–20, which are disordered in the structure. (C) Superposition of phosphate backbones of 5′-E-VPu-TTRRNA
(gold) and miR-20a from its complex with hAgo2 (23) (PDB 4F3T (white)). The sequence of TTR RNA is shown, red indicates 5′-E-VP-modified uridine
nucleotide, bases 1–10 and 21 are shown in gold, and disordered bases 11–20 are shown in gold with black outline. (D) Comparison of the 5′-phosphate
binding pocket in the 5′-E-VPu-modified RNA complex (gold) with the miR-20a complex (white).
the previously reported affinity of a GST-hAgo2 expressed
in Escherichia coli for a single-stranded guide RNA (36).
Since the 5′-E-VPu-modified oligonucleotide cannot be eas-
ily 32P-labeled, we tested binding of the modified RNAs in
a competition assay. Here, hAgo2, unmodified 32P-labeled
TTR guide RNA, and increasing concentrations of unla-
beled 5′-E-VPu-TTR guide were mixed together and as-
sayed in a slot blot apparatus. The 5′-E-VPu-TTR RNA
bound hAgo2 with a dissociation constant of 0.49 nM, ∼2-
fold higher affinity than the 5′-P TTR guide (Figure 2B).
Similarly, the chemically modified 5′-E-VPu-TTR guide
oligonucleotide containing sugar modifications and phos-
phorothiate linkages in addition to the 5′-E-VPu modifica-
tion had a Kd of 0.36 nM, an affinity similar to that of the
oligonucleotide with only the 5′-E-VPu modification, sug-
gesting that the increased affinity is solely the result of the
vinylphosphonate modification (Figure 2C). Moreover, the
affinity of a chemically modified RNA with a 5′-OH (Kd
= 3.8 nM) was about 10 times lower than that of the 5′-E-
VPu-TTR guide (Figure 2D). Taken together, these results
confirm that the 5′-E-VP modification increases the affinity
of the guide RNA for hAgo2 resulting from changes in the
5′ binding pocket that are induced by the vinylphosphonate
modification.
VP-siRNA-GalNAc conjugates are more potent than their 5′-
OH counterparts
Conjugation of a GalNAc ligand to the sense strand of an
siRNA results in accumulation in hepatocytes after sub-
cutaneous administration. For analysis of the effect of the
5′-(E)-vinylphosphonate modification in vitro and in vivo,
we chose to use the well-characterized GalNAc-conjugated
siRNA targeting TTR (8). siRNAs were chemically modi-
fied at specified positions as shown in Table 2. siRNAs with
the 5′-E-VPu modification on the guide strand were com-
pared to those harboring a 5′-hydroxyl (5′-OH). siRNA–
GalNAc conjugates were transfected into primary mouse
hepatocytes and levels of TTR were quantified. As shown
in Table 2, 5′-E-VPu-TTR siRNAwas∼2-fold more potent
than 5′-OH-TTR siRNA. These data are consistent with the
improved binding of the 5′-E-VPu-modified guide RNA.
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Figure 2. Binding affinity of modified and non-modified guide RNAs to hAgo2. (A) In vitro binding of radiolabeled 5′-P-TTR RNA to hAgo2. Fraction
bound as determined by the filter-binding assay is plotted vs. hAgo2 concentration. (B) Competition binding assay of 5′-E-VPu-TTRRNAwith 5′-P-TTR.
Fraction of labeled 5′-P-TTR bound to hAgo2 as a function of 5′-E-VPu-TTR concentration is plotted. (C) Competition binding assay with chemically
modified 5′-E-VPu-TTR (see Table 2 for a list of modifications). (D) Competition binding assay with chemically modified 5′-OH-TTR. Dissociation
constants were calculated from three independent experiments and are presented as means ± standard deviations (SD).
Table 1. Binding affinities of the different guide RNAs to hAgo2
Guide RNA Dissociation constant (Kd)
TTR (no modifications) 1.1 ± 0.09 nM
5′-E-VPu-TTR 0.49 ± 0.05 nM
5′-E-VPu-TTR (fully modified) 0.36 ± 0.01 nM
5′-OH-TTR 3.8 ± 0.29 nM
Dissociation constants of the different guide RNAs tested in Figure 2. Dissociation constants from at least three different experiment are shown as means
± standard devations (sd). For the full list of all the modification for 5′-E-VPu-TTR (fully modified) see Table 2.
Table 2. Double-stranded oligonucleotides used for in vitro and in vivo silencing assays
Conjugate ID Sense strand/guide stranda IC50 (nM)b
5′-OH-TTR 5′-A•a•CaGuGuUCUuGcUcUaUaAGalNAc-3′/
5′-u•U•aUaGaGcAagaAcAcUgUu•u•u-3′
0.06
5′-E-VPu-TTR (fully modified) 5′-A•a•CaGuGuUCUuGcUcUaUaAGalNAc-3′/
5′-VPu•U•aUaGaGcAagaAcAcUgUu•u•u-3′
0.035
aItalicized upper case and normal lower case letters indicate 2′-fluoro (2′-F) and 2′-OMe sugar modifications, respectively. The • indicates a phos-
phorothioate linkage. GalNAc indicates hydroxyprolynyl tri-valent N-acetyl-galactosamine linked as previously reported (8). VP indicates the 5′-(E)-
vinylphosphonate modification.
bHalf-maximal inhibitory concentration (IC50) of siRNA transfected into primary mouse hepatocytes. siRNA-GalNAc conjugates were tested in primary
mouse hepatocytes after lipid transfection. Levels of TTR were quantified by RT-PCR and normalized to levels of GAPDH.
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5′ E-VP-siRNA-GalNAc conjugates reduce TTRmRNA lev-
els and incorporate into hAgo2 better than 5′-OH-siRNA-
GalNAc conjugates in vivo
Next, siRNA-GalNAc conjugates were evaluated for tar-
get silencing in vivo. Mice were treated with a single sub-
cutaneous dose of 1 mg/kg. At 7 days post-dose, 5′-E-VPu-
TTR siRNA reduced levels of liver TTR mRNA by about
85% relative to levels in control mice, whereas the 5′-HO-
TTR siRNA reduced TTR levels by ∼64% (Figure 3A).
To further investigate the effect of the 5′-E-VPu modifica-
tion, we quantified total liver and Ago2-incorporated levels
of the sense and antisense strands as previously described
(29,30). Although total siRNA liver levels for the 5′-HO-
TTR and 5′-E-VPu-TTR GalNAc conjugates were similar
(Figure 3B), the amount of 5′-E-VPu-TTR guide in com-
plex with Ago2 was about 5-fold higher than the amount of
5′-OH guide (Figure 3C). These data suggest that improve-
ment in potency of the 5′-E-VPu-TTR siRNA relative to
the siRNA with a guide strand bearing a 5′-OH was due
to higher level of incorporation of the 5′-E-VPu-TTR guide
strand into a complex with Ago2.
DISCUSSION
The use of siRNAs for therapeutic purposes has revolution-
ized the field of drug discovery, making possible the spe-
cific reduction in levels of otherwise ‘undruggable’ disease-
causing proteins. The two main obstacles for the use of
siRNA-based therapies is the rapid degradation of exoge-
nous RNAs by several cellular mechanisms on the one
hand, and efficient delivery on the other. Several siRNAs
that are currently in clinical testing were designed based on
a strategy that results in safe and effective siRNA deliv-
ery to the liver (6–8). This is achieved by adding a triva-
lent GalNAc ligand conjugated to the 3′ terminus of the
sense (or passenger) strand. In order to overcome their in-
herent instability, siRNAs are strategically modified with
sugar and backbone chemical modifications. Prime among
the limitations of exogenous siRNA activity in vivo is the
rapid removal of the 5′-phosphate of the siRNA. The lack
of a 5′-phosphate results in inefficient incorporation of the
guide strand (antisense strand) into a complex with Ago2
(10), as well as a decrease in the fidelity of target slicing
(1). We have previously shown that the metabolically stable
phosphate mimic 5′-E vinylphosphonate can be used suc-
cessfully to overcome this hurdle and showed higher in vivo
incorporation levels into hAgo2 (10). However, it was still
unclear whether improved incorporation is a result of en-
hancedmetabolic stability conferred by the 5′-E- vinylphos-
phonate modification or better binding to hAgo2 compared
to the ‘natural’ 5′-P.
Using the apo form of hAgo2 we were able to measure
and compare binding affinities of several forms of guide
RNAs to hAgo2. We showed that a guide with a 5′-E-VPu
modification exhibits higher binding affinity to hAgo2 over
both unmodified RNA and a 5′-P-containing RNA. This
provides a rationale for the increased incorporation levels
into hAgo2 and enhanced silencing of the 5′-E-VP modi-
fied RNAs.
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Figure 3. In-vivo quantification of mRNA and hAgo2 incorporated
siRNA levels in the mouse liver. (A) levels of TTR mRNA in liver after
treatment of mice with 5′-OH-TTR siRNA or 5′-E-VPu-TTR siRNA, n=
3. (B) Levels of guide (red) and passenger (blue) strands in livers of mice
treated with 5′-OH-TTR siRNAor 5′-E-VPu-TTR siRNA, n= 3. (C) Lev-
els of Ago2-incorporated guide (red) and passenger (blue) strands in livers
of mice treated with 5′-OH-TTR siRNA or 5′-E-VPu-TTR siRNA, n= 3.
Error bars present standard errors.
In addition, we determined the crystal structure of
hAgo2 in complex with a guide RNA bearing a 5′-E-
vinylphosphanate, 2′-OMe uridine modified nucleotide.
Our crystal structure clearly shows how hAgo2 accom-
modates the modified nucleotide by adjusting the posi-
tion of key residues that interact with the nucleotide while
maintaining all the crucial interactions with the phosphate
group. Indeed, previous studies have shown that despite
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the fact that the 5′-binding pocket in the Mid domain of
hAgo2 is heavily biased towards uracil, it can still bind all
other bases and that higher affinity is mainly achieved by
the presence of the phosphate group (1,37). For that rea-
son we posit that modifications at the 5′-end position of the
guide RNA are possible as long as the critical interactions
with the phosphate moiety (or phosphate mimic) are kept
intact as in the case of the 5′-E-VPu modification presented
here.
While this manuscript was in preparation, a report, de-
scribing the structure of hAgo2 in complex with a chemi-
callymodified guideRNAcarrying a similar 5′–E-VPmodi-
fication on a thymidine nucleotide in addition to otherRNA
modifications, was published (32). Superposition of the two
structures reveals some notable differences in the orienta-
tion of the modified guide RNA between the two structures
(Supplementary Figure S2). First, the orientation of the 5′-
E-VP thymidine in the 5′ binding pocket of hAgo2 is some-
what different than the one we see in the structure described
here (Supplementary Figure S2A). While no change in the
position of the 5′-E-VP is observed, the base and the ribose
groups are shifted by 1 A˚ deeper into the 5′ binding pocket,
a change that is accommodated by a movement of Y529
which is pushed backwards by 1 A˚ compared to our struc-
ture (Supplementary Figure S2B). The shift is likely due to
the presence of the bulkier 2′-O-methoxyethyl (2′-O-MOE)
modification compared to the 2’-OMe in our structure (38–
40), which would otherwise clash with the side chain of
Q548 (Supplementary Figure S2B). This shift in the ribose-
base is accompanied by a repositioning of the phosphoroth-
ioate group between nucleotides 1 and 2 by 1 A˚. There is also
a lengthening of the H-bonds between the phosphoroth-
ioate and the N551 side chain and the amide backbone of
Q548, compared with the normal phosphate, as one might
expect from the different nature of these H-bonds. Finally,
we observed a major change between the structures when
comparing the positions of nucleotides 5 and 6 (the remain-
ing residues were not resolved in the other study).
The guide strand in the two structures takes a different
direction resulting in an increasing difference in position of
0.7–2.9 A˚ up to a 6 A˚ shift of the sugar and nucleobase of
nucleotide 6 compared to the structure presented here. A
similar difference was also noticed by the authors of that
study when compared to an unmodified siRNA with the
same sequence, suggesting that this difference is likely due to
the additional modifications on the siRNA (Supplementary
Figure S2A). Overall, comparing all three structures (un-
modified, the 5′-E-VP-modified, and the extensively mod-
ified guide strands), it is clear that even minor modifica-
tions of 5′-phosphate result in nontrivial adjustments of the
hAgo2 5′-P binding site.
In vivo siRNA loading of hAgo2 is driven by the use
of short RNA duplexes (41,42), and requires the assis-
tance of several other components such as Dicer, TRBP
and the chaperon machinery (43–46), while hAgo2 load-
ing in vitro requires a 5′-phosphorylated 20–23mer single-
stranded RNA and the Argonaute protein (minimal RISC)
without the need for any additional components (1). Our
results indicate that 5′-E-VPu modified siRNAs can be ef-
ficiently loaded into hAgo2 and are superior to those car-
rying the natural 5′-P in vitro as well as in vivo. More-
over, the 5′-E-VPu modification that was used in GalNAc-
conjugated siRNAs proved to be more efficient in silenc-
ing the endogenous levels of transthyretin (TTR) mRNA in
mice compared to the same modified RNA with a 5′-OH
instead of the 5′-E-VPu. Finally, we believe that since the
hAgo2-guide RNA complex is extremely stable in vitro (23)
and long lived in vivo (47,48), a combination of the increased
metabolic stability of the modified RNAs, the inherent re-
silience of the hAgo-guide RNA complex and improved in-
corporation levels to hAgo2 could result in the enhanced
and long lasting silencing effects of these molecules as ther-
apeutic agents.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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